U.S., Jan. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07327021) titled 'MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC' on Nov. 20, 2025.
Brief Summary: Breast cancer is the most common malignancy among women worldwide. Triple-negative breast cancer (TNBC), defined by the lack of estrogen receptor, progesterone receptor, and HER2 expression, comprises approximately 15% of all breast cancers and is the most aggressive subtype, associated with a higher risk of early recurrence and death compared to other breast cancer subtypes. Neoadjuvant chemotherapy (NACT), administered before definitive surgery, is the standard of care for stage II-III TNBC (eTNBC), and pathological complete respon...